COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Expanded Access for AG-221

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03723057
Expanded Access Status : No longer available
First Posted : October 29, 2018
Last Update Posted : October 24, 2019
Information provided by (Responsible Party):

Brief Summary:
This is an expanded access program (EAP) for eligible participants designed to provide access to AG-221.

Condition or disease Intervention/treatment
Acute Myeloid Leukemia Drug: AG-221

Layout table for study information
Study Type : Expanded Access
Expanded Access Type : Individual Patients
  See clinical trials of the intervention/treatment in this expanded access record.
Official Title: Expanded Access for AG-221

Intervention Details:
  • Drug: AG-221
    Oral AG-221 administered as directed by treating physician.
    Other Name: CC-90007; Enasidenib; Idhifa

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All

Inclusion Criteria:


Exclusion Criteria:


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03723057

Layout table for location information
United States, New Jersey
Summit, New Jersey, United States, 07901
Sponsors and Collaborators
Layout table for additonal information
Responsible Party: Celgene Identifier: NCT03723057    
Other Study ID Numbers: AG-221
First Posted: October 29, 2018    Key Record Dates
Last Update Posted: October 24, 2019
Last Verified: October 2019
Keywords provided by Celgene:
Expanded Access
Compassionate Use